A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

~9 mi. (Georgsmarienhütte, Germany, +172 more cities)

Franziskus-Hospital Harderberg

RET Fusion

Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

~9 mi. (Georgsmarienhütte, Germany, +94 more cities)

MVZ II der Niels Stensen Kliniken

HER2 Negative

Breast Carcinoma

sacituzumab govitecan

chemotherapy, +1 more type

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

~9 mi. (Georgsmarienhütte, Germany, +184 more cities)

Franziskus-Hospital Harderberg

RET Fusion

Non-Squamous Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

~14 mi. (Halle, Germany, +93 more cities)

Krankenhaus Martha Maria Halle-Doelau ( Site 0507)

Bladder Carcinoma, +1 more condition

cisplatin, +4 more drugs

chemotherapy, +3 more types

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

~14 mi. (Halle, Germany, +93 more cities)

Krankenhaus Martha Maria Halle-Doelau ( Site 1314)

Clear Cell Renal Cell Carcinoma

belzutifan, +1 more drug

targeted therapy

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer

~14 mi. (Halle, Germany, +151 more cities)

GSK Investigational Site

Non-Small Cell Lung Carcinoma

niraparib, +1 more drug

immunotherapy, +1 more type

Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants

~14 mi. (Halle, Germany, +71 more cities)

GSK Investigational Site

Non-Small Cell Lung Carcinoma

cobolimab, +2 more drugs

chemotherapy, +1 more type

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

~14 mi. (Halle, Germany, +72 more cities)

Universitätsklinikum Halle

del(11)(q10), +27 more biomarkers

Primary Myelofibrosis, +1 more condition

navtemadlin

targeted therapy

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

~14 mi. (Halle, Germany, +57 more cities)

GSK Investigational Site

Non-Squamous Non-Small Cell Lung Carcinoma, +1 more condition

cobolimab, +7 more drugs

chemotherapy, +2 more types

TL-895 and KRT-232 Study in Acute Myeloid Leukemia

~14 mi. (Halle, Germany, +21 more cities)

University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology

FLT3 Codon 835 Missense, +2 more biomarkers

Acute Myeloid Leukemia

navtemadlin, +1 more drug

targeted therapy

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

~25 mi. (Gütersloh, Germany, +180 more cities)

Exelixis Clinical Site #98

Prostate Adenocarcinoma

atezolizumab, +1 more drug

immunotherapy, +1 more type

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

~34 mi. (Münster, Germany, +226 more cities)

Universitaetsklinikum Muenster ( Site 0320)

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type